1
|
Jiang X, Wang F, Wang Y, Gisterå A, Roy J, Paulsson-Berne G, Hedin U, Lerman A, Hansson GK, Herrmann J, Yan ZQ. Inflammasome-Driven Interleukin-1α and Interleukin-1β Production in Atherosclerotic Plaques Relates to Hyperlipidemia and Plaque Complexity. JACC Basic Transl Sci 2019; 4:304-317. [PMID: 31312755 PMCID: PMC6610158 DOI: 10.1016/j.jacbts.2019.02.007] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Revised: 11/24/2018] [Accepted: 02/11/2019] [Indexed: 01/21/2023]
Abstract
Genetic and functional evidence suggests that there are additional inflammasome pathways, besides NLRP3, that contribute to IL-1 generation in human atherosclerotic plaques. Plaque generation of mature IL-1β is accompanied by secretion of similar levels of IL-1α, through a mechanism controlled by NLRP3 and caspase-1. Plaque IL-1β production is higher in patients with uncontrolled hyperlipidemia, on no or low-dose statin therapy, or with complex plaque imaging features. The present study lends support to high-intensity cholesterol lowering and anti-IL-1-directed therapies for patients at high cardiovascular risk.
CANTOS (Canakinumab Antiinflammatory Thrombosis Outcome Study) confirmed interleukin (IL)–1β as an appealing therapeutic target for human atherosclerosis and related complications. However, there are serious gaps in our understanding of IL-1 production in atherosclerosis. Herein the authors show that complex plaques, or plaques derived from patients with suboptimally controlled hyperlipidemia, or on no or low-intensity statin therapy, demonstrated higher recruitable IL-1β production. Generation of mature IL-1β was matched by IL-1α release, and both were attenuated by inhibition of NLR family pyrin domain containing 3 or caspase. These findings support the inflammasome as the main pathway for IL-1α/β generation in atherosclerosis and high-intensity lipid-lowering therapies as primary and additional anti-IL-1-directed therapies as secondary interventions in high-risk patients.
Collapse
Key Words
- ASC, apoptosis-associated speck-like protein containing a CARD
- ATP, adenosine 5′-triphosphate disodium salt hydrate
- BiKE, Biobank of Karolinska Carotid Endarterectomies
- CT, Computerized tomographic scanning
- IL, interleukin
- LDL, low-density lipoprotein
- LPS, lipopolysaccharide
- NLRC, nucleotide-binding oligomerization domain, leucine-rich repeat and CARD domain–containing protein
- NLRP, nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain–containing protein
- PBS, phosphate-buffered saline
- atherosclerosis
- hypercholesterolemia
- inflammasome
- inflammation
- interleukin-1
- mRNA, messenger ribonucleic acid
Collapse
Affiliation(s)
- Xintong Jiang
- Experimental Cardiovascular Research Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Feilong Wang
- Department of Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
| | - Yajuan Wang
- Experimental Cardiovascular Research Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Anton Gisterå
- Experimental Cardiovascular Research Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Joy Roy
- Department of Vascular Surgery, Karolinska University Hospital, Stockholm, Sweden
| | - Gabrielle Paulsson-Berne
- Experimental Cardiovascular Research Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Ulf Hedin
- Department of Vascular Surgery, Karolinska University Hospital, Stockholm, Sweden
| | - Amir Lerman
- Department of Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
| | - Göran K Hansson
- Experimental Cardiovascular Research Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Joerg Herrmann
- Department of Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
| | - Zhong-Qun Yan
- Experimental Cardiovascular Research Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|